Previous Close | 1.6000 |
Open | 1.3200 |
Bid | 0.9500 |
Ask | 1.5500 |
Strike | 12.00 |
Expire Date | 2024-11-15 |
Day's Range | 1.3200 - 1.3200 |
Contract Range | N/A |
Volume | |
Open Interest | 42 |
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.